Literature DB >> 22403811

NICE guidance on rituximab for first-line treatment of symptomatic stage III-IV follicular lymphoma in previously untreated patients.

Sally Doss, Zoe Garrett, Frances Sutcliffe, Andrew Stevens.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22403811     DOI： 10.1016/s1470-2045(12)70009-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Rituximab for non-Hodgkin's lymphoma: a story of rapid success in translation.

Authors:  Andrew M Harrison; Nassir M Thalji; Alexandra J Greenberg; Carmen J Tapia; Anthony J Windebank
Journal:  Clin Transl Sci       Date:  2013-10-03       Impact factor: 4.689

2.  Linking signaling pathways to transcriptional programs in breast cancer.

Authors:  Hatice U Osmanbeyoglu; Raphael Pelossof; Jacqueline F Bromberg; Christina S Leslie
Journal:  Genome Res       Date:  2014-09-02       Impact factor: 9.043

Review 3.  The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies.

Authors:  Gilbert O Fruhwirth; Manfred Kneilling; I Jolanda M de Vries; Bettina Weigelin; Mangala Srinivas; Erik H J G Aarntzen
Journal:  Mol Imaging Biol       Date:  2018-10       Impact factor: 3.488
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.